CXCR4 antagonism ameliorates leukocyte abnormalities in a preclinical model of WHIM syndrome
Our study provides comprehensive evidence that oral dosing with a CXCR4 antagonist can effectively correct WHIM-associated neutrophil and lymphocyte abnormalities in a mouse model of WHIM syndrome. These findings extend our understanding of how targeting the dysregulated CXCR4 signaling pathway can ameliorate the pathogenesis of WHIM syndrome.
Authors
- Lilian Roland (ORCID: https://orcid.org/0000-0003-4079-1911)
- Zeina Abou Nader (ORCID: https://orcid.org/0009-0008-6264-2574)
- Arthur G. Taveras
- Barbara Maierhofer
- Chi Huu Nguyen (ORCID: https://orcid.org/0000-0003-4125-224X)
- Vanessa Gourhand
- Katarina Zmajkovicova (ORCID: https://orcid.org/0000-0002-1394-7039)
- Karl Balabanian (ORCID: https://orcid.org/0000-0002-0534-3198)
- Robert Johnson (ORCID: https://orcid.org/0000-0002-3041-0030)
- Maria Kalogeraki (ORCID: https://orcid.org/0000-0001-7457-7775)
- Mélanie Khamyath
- Halenya Monticelli (ORCID: https://orcid.org/0000-0001-6972-8698)
- Bérénice Schell (ORCID: https://orcid.org/0000-0002-1641-3366)
- Marion Espéli (ORCID: https://orcid.org/0000-0001-5005-1664)
- Vincent Rondeau (ORCID: https://orcid.org/0000-0002-9513-5703)
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Hôpital Saint-Louis (FR)
- Institut de recherche Saint-Louis (FR)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-11
- DOI
- https://doi.org/10.3389/fimmu.2024.1468823
- Citations
- 3
- Primary Topic
- Chemokine receptors and signaling
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Agence Nationale de la Recherche
- Institut National de la Santé et de la Recherche Médicale
- Ligue Contre le Cancer